Psychiatric pharmacogenomic testing in clinical practice.
The clinical adoption of psychiatric pharmacogenomic testing has taken place rapidly over the past 7 years. Initially, drug-metabolizing enzyme genes, such as the cytochrome P450 2D6 gene (CYP2D6), were identified. Genotyping the highly variable cytochrome P450 2D6 gene now provides clinicians with the opportunity to identify both poor metabolizers and ultrarapid metabolizers of 2D6 substrate medications. Subsequently, genes influencing the pharmacodynamic response of medications have been made available for clinical practice. Among the earliest "target genes" was the serotonin transporter gene (SLC6A4) which has variants that have been shown to influence the clinical response of patients of European ancestry when they are treated with selective serotonin reuptake inhibitors. Genotyping of some of the serotonin receptor genes is also available to guide clinical practice. The quantification of the clinical utility of pharmacogenomic testing is evolving, and ethical considerations for testing have been established. Given the increasingly clear cost-effectiveness of genotyping, it has recently been predicted that pharmacogenomic testing will routinely be ordered to guide the selection and dosing of psychotropic medications.
Mrazek
David A
DA
Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA. mrazek.david@mayo.edu
D002986:Clinical Trials as Topic / Q000379:methods*; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy* / Q000235:genetics*; D010597:Pharmacogenetics / Q000379:methods*; D050486:Serotonin Plasma Membrane Transport Proteins / Q000235:genetics; D044465:White People
D050486:Serotonin Plasma Membrane Transport Proteins; D019389:Cytochrome P-450 CYP2D6